evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

9 questions · 9 findings · 1 reviews · Airways

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 7 · 77.8%High 2 · 22.2%

Mepolizumab 100 mg vs placebo

Rate of moderate or severe exacerbations Eosinophilic phenotype · patients with chronic obstructive pulmonary disease

Mepolizumab 100 mg leads to lower rate of moderate or severe exacerbations Eosinophilic phenotype compared with placebo (high certainty).

1 finding from 1 review

Mepolizumab 100 mg vs placebo

Moderate‐to‐severe exacerbations (rate) · patients with chronic obstructive pulmonary disease

Mepolizumab 100 mg showed no clear difference in rate of moderate or severe exacerbations All participants compared with placebo (moderate certainty).

1 finding from 1 review

Mepolizumab 100 mg vs placebo

Time to first moderate or severe exacerbation Eosinophilic phenotype · patients with chronic obstructive pulmonary disease

Mepolizumab 100 mg leads to lower time to first moderate or severe exacerbation Eosinophilic phenotype compared with placebo (high certainty).

1 finding from 1 review

Mepolizumab 100 mg vs placebo

Time to first moderate or severe exacerbation All participants · patients with chronic obstructive pulmonary disease

Mepolizumab 100 mg showed no clear difference in time to first moderate or severe exacerbation All participants compared with placebo (moderate certainty).

1 finding from 1 review

Mepolizumab 100 mg vs placebo

Rate of exacerbations with ED visit or hospitalisations Eosinophilic phenotype · patients with chronic obstructive pulmonary disease

Mepolizumab 100 mg showed no clear difference in rate of exacerbations with ED visit or hospitalisations Eosinophilic… compared with placebo (moderate certainty).

1 finding from 1 review

Mepolizumab 100 mg vs placebo

Rate of exacerbations requiring emergency department treatment or admission · patients with chronic obstructive pulmonary disease

Mepolizumab 100 mg showed no clear difference in rate of exacerbations with ED visit or hospitalisations All… compared with placebo (moderate certainty).

1 finding from 1 review